新型胆固醇吸收抑制剂Ezetimibe的研究进展

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (3): 258-261.

新型胆固醇吸收抑制剂Ezetimibe的研究进展

张新波^1,2, 王绿娅¹

¹北京市安贞医院心肺血管疾病研究所动脉粥样硬化研究室, 北京100029;
²南华大学心血管病研究所, 衡阳421001, 湖南

收稿日期:2006-06-13 修回日期:2007-02-26 出版日期:2007-03-26 发布日期:2020-11-06
通讯作者: 王绿娅, 女, 研究员, 硕士生导师, 研究方向:动脉粥样硬化病理生理。Tel:010-64456436 E-mail:wangluya@sina.com
作者简介:张新波, 男, 在读硕士, 研究方向:动脉粥样硬化病理生理。Tel:13488699970 E-mail:zhangxinbo823@yahoo.com.cn
基金资助:
国家自然科学基金(30470722);北京市自然科学基金(7062010和7052021);北京市科技新星项目(04B27和05A29)

Review of new cholesterol absorption inhibitor ezetimibe

ZHANG Xin-bo^1,2, WANG Lv-ya¹

¹Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029, China;
²Institute of Cardiovascular Diseases, Nan-Hua University, Hengyang 421001, Hunan, China

Received:2006-06-13 Revised:2007-02-26 Online:2007-03-26 Published:2020-11-06

摘要/Abstract

摘要： Ezetimibe 是一种新型选择性肠胆固醇吸收抑制剂, 通过抑制肠上皮细胞的胆固醇吸收蛋白NPC1L1 减少胆固醇、植物固醇的吸收以及胆汁胆固醇的再吸收, 从而降低血浆固醇水平。Ezetimibe 的作用与他汀类药物抑制胆固醇合成的机制互补, 在降低血浆低密度脂蛋白胆固醇和总胆固醇水平的同时, 升高高密度脂蛋白胆固醇水平, 为高胆固醇血症的治疗、动脉粥样硬化和冠心病的防治提供了一种新的有效选择。

关键词: ezetimibe, 高胆固醇血症, 胆固醇吸收抑制剂, NPC1L1

Abstract: Ezetimibe, a new selective cholesterol absorption inhibitor, may decrease the absorption of cholesterol and plant sterol by inhibiting the cholesterol absorption protein Niemann-Pick C1 like 1 (NPC1L1) in the enterocytes.Ezetimibe apparently reduces the plasma low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) level, which provides a new approach for the therapy of hypercholesterolaemia, artherosclerosis and coronary artery disease.

Key words: ezetimibe, hypercholesterolaemia, cholesterol absorption inhibitor, NPC1L1

中图分类号:

R541.4

张新波, 王绿娅. 新型胆固醇吸收抑制剂Ezetimibe的研究进展[J]. 中国临床药理学与治疗学, 2007, 12(3): 258-261.

ZHANG Xin-bo, WANG Lv-ya. Review of new cholesterol absorption inhibitor ezetimibe[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 258-261.

参考文献

1 Patrick JE, Kosoglou T, Stauber KL, et al.Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects[J].Drug Metab Dispos, 2002;30:430-437.
2 Yu L, von Bergmann K, Lutjohann D, et al.Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8 [J].J Lipid Res, 2005;46:1739-1744.
3 Mardones P, Quinones V, Amigo L, et al.Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice[J].J Lipid Res, 2001;42:170-180.
4 Plosch T, Kok T, Bloks VW, et al.Increased Hepatobiliary and fecal cholesterol excretion upon activation of the liver x receptor is independent of ABCA1[J].J Biol Chem, 2002;277: 33870-33877.
5 Smart EJ, De Rose RA, Farber SA.Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport[J].PNAS, 2004;101:3450-3455.
6 Valasek MA, Weng J, Shaul PW, et al.Caveolin-1 is not required for murine intestinal cholesterol transport[J].J Biol Chem, 2005;280:28103-28109.
7 Altmann SW, Davis HR Jr, Zhu LJ, et al.Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption[J]. Science, 2004;303:1201-1204.
8 Garcia-Calvo M, Lisnock J, Bull HG, et al.The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) [J].PNAS, 2005;102:8132-8137.
9 Sane AT, Sinnett D, Delvin E, et al.Localization and role of NPC1L1 in cholesterol absorption in human intestine[J].J Lipid Res, 2006;47:2112-2120.
10 Yamanashi Y, Takada T, Suzuki H.Niemann-Pick C1-Like 1 overexpression facilitates ezetimibe-sensitive cholesterol and β-sitosterol uptake in CaCo-2 Cells[J].J Pharmacol Exp Ther, 2007;320:559-564.
11 Davis HR Jr, Zhu LJ, Hoos LM, et al.Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis [J].J Biol Chem, 2004;279:33586-33592.
12 Davis HR Jr, Hoos LM, Tetzloff G, et al.Deficiency of Niemann-Pick C1-Like 1 prevents atherosclerosis in ApoE-/-mice [J].Arterioscler Thromb Vasc Biol, 2007:841-849.
13 Knopp RH, Gitter H, Truitt T, et al.Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia[J].Eur Heart J, 2003;24: 729-741.
14 Bays HE, Moore PB, Drehobl MA, et al.Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia:pooled analysis of two phase II studies[J].Clin Ther, 2001;23:1209-1230.
15 Ballantyne CM, Houri J, Notarbartolo A, et al.Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double-blind trial[J].Circulation, 2003;107:2409-2415.
16 Bissonnette S, Habib R, Sampalis F, et al.Efficacy and tolerability of ezetimibe 10 mg day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy:A Canadian, multicentre, prospective study--the Ezetrol Add-On Study[J].Can J Cardiol, 2006;22:1035-1044.
17 Gagne C, Gaudet D, Bruckert E, et al.Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia[J].Circulation, 2002;105:2469-2475.
18 Salen G, von Bergmann K, Lutjohann D, et al.Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia[J].Circulation, 2004;109:966-971.
19 Ballantyne CM, Lipka LJ, Sager PT, et al.Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia [J].Int J Clin Pract, 2004;58:653-658

[1]	郑少微，巩付华，展淑琴，孙宏，杜赟，李燕玲，吴海琴，张桂莲. Evolocumab治疗高胆固醇血症患者安全性的Meta分析[J]. 中国临床药理学与治疗学, 2016, 21(5): 520-525.
[2]	闫莉萍, 陈舜宏, 陈伟民, 陈士林, 马小军, 徐宏喜. 葛根素对膳食诱导的高胆固醇血症大鼠的血脂调节作用[J]. 中国临床药理学与治疗学, 2006, 11(5): 574-577.
[3]	李景荣, 熊术道, 李玉光, 张元春. 氨氯地平对高胆固醇大鼠心肌缺血再灌注时一氧化氮合酶的影响[J]. 中国临床药理学与治疗学, 2004, 9(8): 901-905.
[4]	王倩, 汪海. 调节内皮细胞功能的新化合物哌芳安他抗动脉粥样硬化作用¹[J]. 中国临床药理学与治疗学, 2003, 8(4): 374-380.
[5]	董敏, 刘中兴. 氟化他汀钠治疗高胆固醇血症65 例[J]. 中国临床药理学与治疗学, 2001, 6(3): 281-281.
[6]	陈珊, 单江, 金宏义, 谢海宝, 秦南屏, 李佩璋, 阮邹荣. 国产与进口辛伐他汀治疗原发性高胆固醇血症疗效比较[J]. 中国临床药理学与治疗学, 2000, 5(1): 36-38.